Sonepcizumab With VEGF Inhibitors Improves Overall Survival in mRCC

Share this content:
Sonepcizumab improves overall survival of patients with metastatic renal cell carcinoma.
Sonepcizumab improves overall survival of patients with metastatic renal cell carcinoma.

In conjunction with vascular endothelial growth factor (VEGF) inhibitors, sonepcizumab improves overall survival of patients with metastatic renal cell carcinoma (mRCC), according to a study published in Cancer.1

mRCC is usually incurable, despite several advances in treatment in recent years. VEGF inhibitors improve progression-free survival, but tumors evolve resistance to these drugs. For the present study, researchers evaluated whether sonepcizumab, a monoclonal antibody, can limit tumor resistance to VEGF-directed therapy.

Forty patients, 30 of whom had metastatic disease, were enrolled to this phase 2 trial between May 2013 and December 2014. When the study was discontinued in September 2015, median progression-free survival was 2.2 months, and the median overall survival was 21.7 months. No complete responses were reported.

RELATED: Adjuvant Sunitinib Prolongs DFS in High-risk Locoregional Renal Cell Carcinoma

No grade 3-4 treatment-related adverse events were observed; fatigue was the most common grade 1-2 event, which was reported for 12 patients.

The authors conclude that although the primary endpoint was not met, the improvement in overall survival is encouraging. Sonepcizumab should be investigated further as a complement to PD-1 and PD-L1 inhibitors, in addition to VEGF inhibitors.

Reference

  1. Pal SK, Drabkin HA, Reeves JA, et al. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. Cancer. 2016 Oct 11. doi: 10.1002/cncr.30393 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs